Everolimus 5mg Everolimus is a kinase inhibitor indicated for the treatment of: 1. Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of letrozole or anastrozole.

Everolimus is a rapamycin analog that is widely used in the treatment of cancer and tuberous sclerosis. The following is a detailed description of Everolimus:

Indications

Everolimus is indicated for the treatment of patients with:

1. Advanced renal cell carcinoma : Suitable for adult patients who have failed previous treatment with sunitinib or sorafenib.

2. Pancreatic neuroendocrine tumors : Indicated for adult patients with unresectable, locally advanced or metastatic, well-differentiated (moderately differentiated or well-differentiated) advanced pancreatic neuroendocrine tumors.

3. Tuberous sclerosis complex-associated subependymal giant cell astrocytoma (SEGA) : Indicated for adult and pediatric patients who require therapeutic intervention but are not suitable for surgical resection.

This product should be used for treatment under the guidance of a physician with experience in treating tumors or tuberous sclerosis.

Dosage

The recommended dose is 10 mg once daily. This product is taken orally once daily at the same time every day, with or without food.

Adverse Reactions

Common adverse reactions include:

• Stomatitis

• rash

• Fatigue

• diarrhea

• Infect

• Dyslipidemia

• Increased blood sugar

Patients should regularly monitor their blood routine, liver and kidney function, and blood sugar and blood lipid levels while using this product.

Precautions

• Risk of infection : Everolimus may increase the risk of infection and care should be taken to prevent infection during use.

• Abnormal liver function : The use of this product may cause abnormal liver function. It is recommended to monitor liver function regularly.

• Impaired renal function : This product may affect renal function and renal function indicators should be monitored during use.

Contraindications

Patients with hypersensitivity to everolimus or any of its components are contraindicated.

Drug interactions

Everolimus is mainly metabolized by CYP3A4 and P-gp, and strong CYP3A4 inhibitors or inducers may affect its blood concentration. Caution should be exercised when used in combination with these drugs, and the dose should be adjusted as needed.

Pregnant and lactating women

Pregnant women using this product may cause harm to the fetus, so it is recommended to avoid using it during pregnancy. It is not clear whether everolimus is secreted through breast milk, so breastfeeding women should consider stopping breastfeeding when using this product.

Children's medication

The safety and effectiveness for pediatric patients have not been fully established and should be used with caution.

Medication for the elderly

Elderly patients do not need to adjust the dosage of this product, but should be closely monitored for the occurrence of adverse reactions.

Overdose

There is currently no specific antidote for everolimus overdose; supportive treatment should be given in the event of an overdose.

Storage conditions

This product should be stored below 25°C away from moisture and direct sunlight.

Please read the drug instructions carefully before use and follow the doctor's instructions for treatment.